News tagged with novartis
Chip-in-a-pill may be approved in 2012
(PhysOrg.com) -- Giant Swiss pharmaceutical company Novartis AG, based in Basel, is developing a pill containing an embedded microchip, which it hopes to submit for regulatory approval in Europe within 18 ...
Medicine & Health / Medications
Nov 10, 2010 |
4.9 / 5 (18) |
10
|
Continuous drug manufacturing offers speed, lower costs
Traditional drug manufacturing is a time-consuming process. Active pharmaceutical ingredients are synthesized in a chemical manufacturing plant and then shipped to another site, where they are converted into ...
Mar 12, 2012 |
5 / 5 (4) |
0
Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging
(PhysOrg.com) -- A first-line treatment for relapsing forms of multiple sclerosis (MS) was approved in September 2010 by the US Food and Drug Administration: FTY720 (fingolimod, Gilenya), which acts as a sphingosine ...
Feb 04, 2011 |
5 / 5 (3) |
0
UNICEF discloses vaccine prices for 1st time
UNICEF is for the first time publicizing what drugmakers charge it for vaccines, as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs.
Medicine & Health / Medications
May 29, 2011 |
5 / 5 (3) |
1
Scientists identify new class of antimalarial compounds
An international team led by scientists from the Genomics Institute of the Novartis Research Foundation (GNF) and The Scripps Research Institute has discovered a family of chemical compounds that could lead ...
Nov 17, 2011 |
3 / 5 (2) |
2
|
Switzerland restricts use of GlaxoSmithKline swine flu vaccine
Switzerland on Friday restricted the use of British drugs group GlaxoSmithKline's swine flu vaccine Pandemrix, excluding pregnant women, minors and people over the age of 60.
Medicine & Health / Medications
Oct 30, 2009 |
2.5 / 5 (2) |
0
Novartis says swine flu vaccine boosts profit
Swiss pharmaceutical group Novartis posted on Tuesday an 8.0-percent jump in core annual net profit for 2009, saying that business had been boosted by sales of swine flu vaccine.
Jan 26, 2010 |
5 / 5 (1) |
0
Novartis fined $422.5M in marketing, kickback case
(AP) -- Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, ...
Medicine & Health / Medications
Sep 30, 2010 |
5 / 5 (1) |
0
Novel epigenetic patterns involved in cell fate regulation
(PhysOrg.com) -- Scientists from the Friedrich Miescher Institute for Biomedical Research (FMI) publish exciting new results on the regulation of cell fate in the scientific journal Nature. They identified ...
Dec 15, 2011 |
5 / 5 (1) |
0
|
New steps toward a universal flu vaccine
Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their ...
Medicine & Health / Medical research
May 19, 2010 |
4 / 5 (1) |
0
Novartis starts testing swine flu vaccine
(AP) -- Swiss drugmaker Novartis has begun injecting its swine flu vaccine into people in the company's first human tests, a spokesman said Wednesday. The vaccine is being tested in a yearlong trial of 6,000 ...
Medicine & Health / Medications
Aug 05, 2009 |
3 / 5 (1) |
1
IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed ...
Medicine & Health / HIV & AIDS
Feb 10, 2009 |
2 / 5 (1) |
0
Extending the shelf life of antibody drugs
A new computer model developed at MIT can help solve a problem that has plagued drug companies trying to develop promising new treatments made of antibodies: Such drugs have a relatively short shelf life because they tend ...
Medicine & Health / Medical research
Jun 29, 2009 |
2 / 5 (1) |
1
Seasonal flu vaccine shipping early, demand up
(AP) -- The swine flu pandemic is spurring makers of seasonal flu vaccines to ship them to the U.S. market well ahead of schedule, and supplies are tightening as distributors and others snap up vaccine vials.
Medicine & Health / Medications
Aug 06, 2009 |
1 / 5 (1) |
0
Novartis
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.172 billon in 2008 . Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
For more information about Novartis, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
